한빛사논문
- 조회209
Bu Gyeom Kim1,4, Bo Ram Kim1,4, Dae Yeong Kim1,2, Woo Young Kim3, Sanghee Kang3, Sun Il Lee3, Sang Cheul Oh1,4
1Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, 08308, Republic of Korea
2Department of Biomedical Sciences, Korea University College of Medicine, Seoul, 02841, Republic of Korea
3Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, 08308, Republic of Korea
4Institute of Convergence New Drug Development, Korea University College of Medicine, Seoul, 02841, Republic of Korea
Corresponding author: Sang Cheul Oh
Abstract
The treatment of patients with triple negative breast cancer (TNBC) relies on cytotoxic therapy. Currently, atezolizumab and chemotherapy can be combined in patients with TNBC. However, this approach is not effective for all patients with low reactivity to atezolizumab. As there is a lack of alternative treatment options, new anti-cancer drugs are urgently needed to enhance atezolizumab reactivity against TNBC. Recent strategies have focused on regulating the expression of programmed death-ligand 1 (PD-L1) or enhancing immune response activation by combining anti-cancer drugs with immune checkpoint inhibitors (ICIs). Cannabidiol (CBD), a cannabinoid component derived from the cannabis plant, has been reported to have anti-cancer therapeutic potential because of its capacity to induce apoptotic cell death in tumor cells while avoiding cytotoxicity in normal cells. Previous studies have demonstrated the effects of CBD on apoptosis in various cancer cell types. However, the potential role of CBD as an immune modulator in the regulation of PD-L1 expression and anti-cancer immune responses remains to be explored. In this study, we found that CBD stimulated PD-L1 expression in TNBC cells, which significantly induced the CBD-mediated cGAS-STING pathway activation. Taken together, we demonstrated that the combination of CBD and anti-PD-L1 antibody enhances the anti-cancer immune response in vitro and in vivo experiments. Our findings identified the mechanism of PD-L1 regulation by CBD in TNBC cells and suggested that CBD could be a potential candidate for the development of new combinatorial strategies with ICIs in TNBC patients.
논문정보
- Research article
- 2024년 09월 (BRIC 등록일 2024-09-20)
- 국내 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
